Regulation - UCB

Filter

Current filters:

UCB

Popular Filters

Actavis confirms Vimpat patent challenge and gets OK for generic Opana

15-07-2013

US generics major Actavis (NYSE: ACT) confirmed on Friday (July 12) that it has filed an Abbreviated…

ActavisEndo Health SolutionsGenericsLegalNeurologicalNorth AmericaOpana ERPatentsRegulationUCBVimpat

UCB files for US and EU approval for Cimzia for psoriatic arthritis and axial spondyloarthritis

20-02-2013

Belgium's largest drugmaker, UCB (Euronext Brussels: UCB) says it has made two new regulatory filings…

Anti-Arthritics/RheumaticsCimziaEuropeNorth AmericaPharmaceuticalRegulationUCB

FDA approves UCB drug Neupro for PD and RLS

03-04-2012

Belgian drugmaker UCB (Euronext Brussels: UCB) said yesterday that the US Food and Drug Administration…

NeuproNeurologicalNorth AmericaPharmaceuticalRegulationUCB

UCB’s Vimpat syrup recalled in EU due to batch defect

25-07-2011

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has agreed to a…

EuropeNeurologicalPharmaceuticalRegulationUCBVimpat

Back to top